- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Interventions
- ALN-PNP, Tirzepatide, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Coronado, California • Pasadena, California • Metairie, Louisiana + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis, Liver Disease Parenchymal
- Interventions
- Quantitative ultrasound (DeepUSFF)
- Device
- Lead sponsor
- Seoul National University Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boardman, Ohio
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
- Interventions
- Semaglutide Pen Injector, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
- Interventions
- Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
- Drug · Diagnostic Test
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
- Interventions
- ESG + lifestyle modification, Lifestyle modification
- Device · Behavioral
- Lead sponsor
- Pichamol Jirapinyo, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Morgantown, West Virginia
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Efimosfermin, Placebo
- Drug
- Lead sponsor
- Boston Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 35
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Efimosfermin alfa
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Rialto, California • Tampa, Florida • San Antonio, Texas
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
- Interventions
- Pegozafermin, Placebo
- Biological · Drug
- Lead sponsor
- 89bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 762 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 112 more
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Interventions
- Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B), Placebo (Cohort B)
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 48
- States / cities
- Chandler, Arizona • Tucson, Arizona • Huntington Park, California + 41 more
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- ALN-CIDEB, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chandler, Arizona
- Conditions
- NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
- Interventions
- ALG-055009, Placebo
- Drug
- Lead sponsor
- Aligos Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 40
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 37 more
- Conditions
- Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
- Interventions
- TVB-2640, Placebo
- Drug · Other
- Lead sponsor
- Sagimet Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 103
- States / cities
- Huntsville, Alabama • Madison, Alabama • Sun City, Arizona + 80 more
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
- Interventions
- Efinopegdutide
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 36
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more
- Conditions
- Metabolic-dysfunction-associated Fatty Liver Disease (MAFLD)
- Interventions
- Vibration-controlled transient elastography
- Device
- Lead sponsor
- William Jennings Bryan Dorn VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Columbia, South Carolina
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Efimosfermin alfa, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 47
- States / cities
- Arcadia, California • Covina, California • Los Angeles, California + 37 more
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Efimosfermin Alfa, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 43
- States / cities
- Arcadia, California • Covina, California • Los Angeles, California + 34 more
- Conditions
- Fatty Liver, Nonalcoholic, Weight Loss, Virtual Reality, Implementation Science
- Interventions
- In-person dietary weight loss counseling, Virtual reality dietary weight loss counseling
- Behavioral
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Rezdiffra
- Drug
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- West Conshohocken, Pennsylvania
- Conditions
- Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Plainsboro, New Jersey
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- HU6, Placebo
- Drug · Other
- Lead sponsor
- Rivus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 31
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 25 more
- Conditions
- MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Interventions
- Low-oxalate fixed diet
- Dietary Supplement
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
- Interventions
- Thermoacoustic Enhanced Ultrasound
- Device
- Lead sponsor
- Endra Lifesciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Interventions
- Tirzepatide, Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 141
- States / cities
- Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York